Lombard Medical Inc. (NASDAQ:EVAR) Given $1.75 Consensus Price Target by Brokerages

lombard-medical-inc-nasdaqevar-given-175-consensus-price-target-by-brokerages.jpg

Lombard Medical Inc. (NASDAQ:EVAR) has been given a consensus broker rating score of 3.00 (Hold) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a hold rating. Lombard Medical’s rating score has declined by 50% in the last 90 days as a result of a number of analysts’ upgrades and downgrades.
Brokers have set a 1-year consensus price target of $1.75 for the company and are predicting that the company will post ($0.26) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Lombard Medical an industry rank of 85 out of 265 based on the ratings given to related companies.
Shares of Lombard Medical (NASDAQ:EVAR) traded down 3.37% during trading on Wednesday, hitting $0.86. The stock had a trading volume of 6,171 shares. The firm has a 50 day moving average of $1.09 and a 200 day moving average of $1.21. The company’s market capitalization is $17.03 million. Lombard Medical has a 1-year low of $0.55 and a 1-year high of $4.00.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/07/lombard-medical-inc-nasdaqevar-given-1-75-consensus-price-target-by-brokerages.html

Lombard Medical (NASDAQ:EVAR) last announced its earnings results on Monday, August 22nd. The company reported ($0.42) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.40) by $0.02. The firm earned $3.80 million during the quarter, compared to the consensus estimate of $3.78 million. The business’s quarterly revenue was down 16.1% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.51) EPS. Analysts expect that Lombard Medical will post ($1.31) EPS for the current fiscal year.
A number of brokerages have recently weighed in on EVAR. BTIG Research restated a “hold” rating on shares of Lombard Medical in a research note on Tuesday, August 23rd. Barclays PLC lowered their target price on Lombard Medical from $2.50 to $1.00 and set an “equal weight” rating for the company in a research note on Tuesday, August 23rd.
Lombard Medical, Inc is a medical technology company. The Company specializes in developing, manufacturing, and marketing endovascular stent-grafts for repair of aortic aneurysms. Its lead product, Aorfix, is an abdominal aortic aneurysm (AAA) stent-graft for the treatment of AAAs with angulation at the neck of the aneurysm of up to 90 degrees.
Get a free copy of the Zacks research report on Lombard Medical (EVAR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Lombard Medical Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Lombard Medical Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

Be the first to comment on "Lombard Medical Inc. (NASDAQ:EVAR) Given $1.75 Consensus Price Target by Brokerages"

Leave a comment

Your email address will not be published.

*